Stent restenosis and the use of drug-eluting stents in patients with diabetes mellitus

Current Diabetes Reports

Volumn 4, Issue 1, 2004, Pages 13-19

  Sarembock, Ian J ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN; TICLOPIDINE; TIROFIBAN; BIOMATERIAL;

CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HUMAN; INCIDENCE; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE THROMBOSIS; RESTENOSIS; REVIEW; SURGICAL TECHNIQUE; STENT;

COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; DIABETES COMPLICATIONS; DRUG DELIVERY SYSTEMS; HUMANS; SIROLIMUS; STENTS;

EID: 1642279454     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-004-0005-9     Document Type: Review

References (65)

1. Dotter CT, Judkins MR: Transluminal treatment of arteriosclerotic obstructions. Circulation 1964, 30: 654-670.
2. Teirstein PS, Massullo V, Jani S, et al.: Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997, 336: 1697-1703.
3. George B, Voorhees W, Roubin G, et al.: Multicenter investigation of coronary stenting to treat acute or treated closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. J Am Coll Cardiol 1993, 22: 135-143.
4. Savage M, Fischmann D, Schatz R, et al.: Long-term angiographic and clinical outcome after implantation of a balloon-expandable stent in the native coronary circulation. J Am Coll Cardiol 1994, 24: 1207-1212.
5. Carrozza J, Kuntz R, Levine M, et al.: Angiographic and clinical outcome of intracoronary stenting: immediate and long-term results from a large single-center experience. J Am Coll Cardiol 1992, 20: 328-337.
6. Wong SC, Baim DS, Schatz RA, et al.: Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter Palmaz-Schatz stent experience. The Palmaz-Schatz Stent Study Group. J Am Coll Cardiol 1995, 26: 704-712.
7. Fischman DL, Leon MB, Baim DS, et al.: A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study investigators. N Engl J Med 1994, 331: 496-501.
8. Serruys PW, de Jaegere P, Kiemenjei F, et al.: A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. BENESTENT Study group. N Engl J Med 1994, 331: 489-495.
9. Versaci F, Gaspardone A, Phil M, et al.: A comparison of coronary artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. N Engl J Med 1997, 336: 817-822.
10. Macaya C, Serruys PW, Ruygrok P, et al.: Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow up of BENESTENT trial. BENESTENT Study Group. J Am Coll Cardiol 1996, 27: 255-261.
11. Betriu A, Masotti M, Serra A, et al.: Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four year follow-up. J Am Coll Cardiol 1999, 34: 1498-1506.
12. Erbel R, Hande M, Hopp HW, et al.: Restenosis Stent (REST) study: randomized trial comparing stenting and balloon angioplasty for treatment of restenosis after balloon angioplasty. J Am Coll Cardiol 1996, 27: 139A.
13. Al Suwaidi J, Berger PB, Holmes DR Jr: Coronary artery stents. JAMA 2000, 28: 1825-1836.
14. Batchelor WB, Mahaffey KW, Berger PB, et al.: A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST Trial. J Am Coll Cardiol 2001, 15: 1608-1613.
15. Hoffman R, Mintz GS, Dussaillant GR: Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 1996, 94: 1247-1254.
16. Kastrati A, Schomig A, Dietz R, Neumann FJ: Time course of restenosis during the first year after emergency coronary stenting. Circulation 1993, 87: 1498-1505.
17. Kimura T, Yokoi H, Tamura T, et al.: Three years follow-up after implantation of metallic coronary artery stents. N Engl J Med 1996, 334: 561-566.
18. Lathan RJ, Carrozza JP, Berger JP, et al.: Long-term (4-6 year) outcome of Palmaz-Schatz Stenting. Paucity of late clinical stent-related problems. J Am Coll Cardiol 1996, 28: 820-826.
19. Mehran R, Dangas G, Abizaid AS, et al.: Angiographic patterns of in-stent restenosis: classification and implication for long-term outcome. Circulation 1999, 100: 1872-1878.
20. Mehran R, Dangas G, Mintz G, et al.: Treatment of in-stent restenosis with excimer laser coronary angioplasty vs. rotational atherectomy. Circulation 2000, 101: 2484-2489.
21. Mehran R, Mintz GS, Popma JJ, et al.: Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. Am J Cardiol 1996, 78: 718-722.
22. Mehran R, Dangas G, Abizaid AS, et al.: Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999, 100: 1872-1878.
23. Eltchaninoff H, Koning R, Tron C, et al.: Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate. J Am Coll Cardiol 1998, 32: 980-984.
24. Shiran A, Mintz GS, Waksman R, et al.: Early lumen loss after treatment of in-stent restenosis. An intravascular ultrasound study. Circulation 1998, 98: 200-203.
25. Schiele F, Vuillemenot A, Meneveau N, et al.: Effects of increasing balloon pressure on mechanism and results of balloon angioplasty for treatment of restenosis after Palmaz-Schatz stent implantation: an angiographic and intravascular ultrasound study. Cathet Cardiovasc Intervent 1999, 46: 314-322.
26. Dauerman HL, Baim DS, Cutlip DE, et al.: Mechanical debulking versus balloon angioplasty for the treatment of diffuse in-stent restenosis. Am J Cardiol 1998, 82: 277-284.
27. Kini A, Marmur JD, Duvvuri S, et al.: Rotation atherectomy: improved procedural outcome with evolution of technique and equipment. Single-center results of first 1,000 patients. Catheter Cardiovasc Interv 1999, 46: 305-311.
28. Pathan A, Butte A, Harrell L, et al.: Directional coronary atherectomy is superior to PTCA for the treatment of Palmaz-Schatz stent restenosis. J Am Coll Cardiol 1997, 29(suppl A): 68A.
29. Albiero R, Nishida T, Karvouni E, et al.: Cutting balloon angioplasty for the treatment of in-stent restenosis. Cathet Cardiovasc Intervent 2000, 50: 452-459.
30. Tamai H, Katou K, Yamaguchi T, et al.: The impact of tranilast on restenosis after coronary angioplasty: the second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am Heart J 2002, 143: 506-513.
31. Parananadi SN,Topol EJ: Contemporary clinical trials of restenosis. J Invasive Cardiol 1994, 4: 109-124.
32. Teirstein PS, Massullo V, Jani S, et al.: Three-year clinical and angiographic follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2000, 101: 360-365.
33. Raizner AE, Oesterle SN, Waksman R, et al.: Inhibition of restenosis with beta-emitting radiotherapy: report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation 2000, 102: 951-958.
34. Leon MS, Teirstein PS, Moses JW, et al.: Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001, 344: 350-356.
35. King SB, Williams DO, Chougule P, et al.: Endovascular beta-radiation to reduce restenosis after coronary balloon angioplasty: results of the Beta Energy Restenosis Trial (BERT . Circulation 1998, 97: 2025-2030.
36. Waksman R, White RL, Chan RC, et al.: Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000, 101: 2165-2171.
37. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI . Circulation 1997, 96: 1761-1769.
38. Kip KE, Faxon DP, Detre KM, et al.: Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996, 94: 1818-1825.
39. Kastrati A, Schomig A, Elezi S, et al.: Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997, 30: 1428-1436.
40. Carrozza JP Jr, Kunz RE, Fishman RF, Baim DS: Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993, 118: 344-349.
41. Abizaid A, Kornowski R, Mintz GS, et al.: The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998, 32: 584-589.
42. Elezi S, Kastrati A, Pache J, et al.: Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998, 32: 1866-1873.
43. Van Belle E, Bauters C, Hubert E, et al.: Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native vessels. Circulation 1993, 118: 344-349.
44. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation [no authors listed]. N Engl J Med 1994, 330: 956-961.
45. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators [no authors listed]. N Engl J Med 1997, 336: 1689-1696.
46. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. The CAPTURE Study [no authors listed]. Lancet 1997, 349: 1429-1435.
47. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. The EPISTENT Investigators: Evaluation of Platelet IIb/IIIa Inhibitor for Stenting [no authors listed]. Lancet 1998, 352: 87-92.
48. Marso SP, Lincoff AM, Ellis SG, et al.: Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of Platelet IIb/IIIa inhibitor for stenting trial) Diabetic Substudy. Circulation 1999, 100: 2477-2484.
49. Aronson D, Bloomgarden Z, Rayfield EJ: Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996, 27: 528-535.
50. Roffi M, Moliterno DJ, Meier B, et al.: Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary interventions: do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up? Circulation 2002, 105: 2730-2736.
51. King SB, Lembo NJ, Kosinski AS, et al.: A randomized trial comparing coronary angioplasty with coronary bypass surgery. N Engl J Med 1994, 331: 1044-1050.
52. Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial [no authors listed]. Lancet 1993, 341: 573-580.
53. Rodriguez A, Boullon F, Perez-Balino N, et al.: Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multi-vessel disease (ERACI): in-hospital results and 2 year follow-up. J Am Coll Cardiol 1993, 22: 1060-1067.
54. First year results of CABRI (Coronary Angioplasty vs Bypass Revascularization Investigation) [no authors listed]. Lancet 1995, 346: 1179-1184.
55. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. BARI Investigators [no authors listed]. N Engl J Med 1996, 335: 217-225.
56. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status [no authors listed]. J Am Coll Cardiol 2000, 35: 1122-1129.
57. Laskey WK, Selzer F, Vlachos HA, et al.: Comparison of in-hospital and one year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the NHLBI Dynamic Registry). Am J Cardiol 2001, 90: 1062-1067.
58. Rhatt DL, Maso SP, Lincoff M, et al.: Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000, 35: 922-928.
59. Sedlis SP, Morrison DA, Lorin JD, et al.: Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol 2002, 40: 1555-1566.
60. Loutfi M, Mulvihill NT, Boccalatte M, et al.: Impact of restenosis and disease progression on clinical outcome after multivessel stenting in diabetic patients. Cathet Cardiovasc Intervent 2003, 58: 451-454.
61. Morice MC, Serruys PW, Sousa JE, et al.: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346: 1773-1780.
62. Degertekin M, Serruys PW, Foley DP, et al.: Persistent inhibition if neointimal hyperplasia after sirolimus-eluting stent implantation long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002, 106: 1610-1613.
63. Moses JW, Leon MB, Popma JJ, et al.: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349: 1315-1323.
64. Baim DS, Levine MJ, Leon MB, et al.: Management of restenosis within the Palmaz-Schatz coronary stent (the US multicenter experience). Am J Cardiol 1993, 73:364-366.
65. Colombo A, Drzewiecki J, Banning A, et al.: Randomized study to assess the effectiveness of slow and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003, 108: 788-794.